GMP Audit Checklist: 21 CFR 211 Self-Audit Tool

Table of Contents

Share

TL;DR
  • This free GMP audit checklist covers 53 requirements across 21 CFR Part 211, Subparts B to K, with Compliant, Partial, Not compliant, and N/A scoring.
  • Items tagged with an FDA 483 rank are among the ten Part 211 sections FDA cited most often on drug Form 483s in fiscal year 2025.
  • Your answers and notes save in your browser, and the summary ranks gaps by severity and prints to PDF.
  • Use it for a first-pass self-audit before a mock inspection, customer audit, or FDA inspection.

GMP Audit Checklist (21 CFR 211)

53 questions across 10 subparts. Answers are saved on this device only.

0 answered

21 CFR 211.22 to 211.34. Read the regulation on eCFR.

211.22(a)A quality control unit (QCU) exists with authority to approve or reject components, containers, closures, in-process materials, labeling, and drug products, and to review production records.
211.22(b)Adequate laboratory facilities are available to the QCU for testing and approving materials and products.
211.22(d)QCU responsibilities and procedures are written down, and they are followed in practice.#1 FDA 483 citation
211.25(a)Personnel have the education, training, and experience for their assigned functions, and GMP training is given by qualified people often enough to stay current.
211.28Personnel wear clean, appropriate protective apparel, and anyone with a condition that could affect product safety or quality is excluded from contact with it.
211.34Consultants who advise on manufacturing, processing, packing, or holding have adequate qualifications, and records of their qualifications and services are kept.

21 CFR 211.42 to 211.58. Read the regulation on eCFR.

211.42(b)Facility size, design, and layout allow proper cleaning, maintenance, and operations, with flow that prevents mix-ups and contamination.
211.42(c)Separate or defined areas exist for receipt, quarantine, release, rejection, production, packaging, labeling, and laboratory work.
211.46Ventilation, air filtration, heating, and cooling are adequate, with air pressure, particulate, and microbial controls where appropriate.
211.48Potable water is supplied, and drains are of adequate size with air breaks or other devices to prevent back-siphonage.
211.56Written procedures cover sanitation, cleaning agents, and pest control, and they are followed.
211.58Buildings are maintained in a clean state and good repair.

21 CFR 211.63 to 211.72. Read the regulation on eCFR.

211.63Equipment design, size, and location suit its intended use and allow cleaning and maintenance.#7 FDA 483 citation
211.65(a)Product-contact surfaces are not reactive, additive, or absorptive in a way that alters product quality.
211.67(a)Equipment is cleaned, maintained, and sanitized at appropriate intervals to prevent malfunctions and contamination.#5 FDA 483 citation
211.67(b)Written cleaning and maintenance procedures exist, assign responsibility, define schedules and methods, and are followed.#8 FDA 483 citation
211.68(a)Automatic, mechanical, and electronic equipment, including computers, is routinely calibrated, inspected, or checked under a written program.
211.68(b)Computer systems have controls so that only authorized personnel can change master records or data, input and output are checked for accuracy, and backup data is maintained.#6 FDA 483 citation

21 CFR 211.80 to 211.94. Read the regulation on eCFR.

211.80(a)Written procedures describe receipt, identification, storage, handling, sampling, testing, and approval or rejection of components, containers, and closures.
211.82(b)Incoming materials are held in quarantine until they are tested or examined and released.
211.84(d)At least one identity test is run on each component lot, and supplier certificates of analysis are relied on only after the supplier's results have been validated.
211.86Approved components, containers, and closures are rotated so the oldest approved stock is used first.
211.89Rejected materials are identified and controlled under a quarantine system that prevents their use.
211.94Containers and closures protect the product, are not reactive, additive, or absorptive, and meet written specifications.

21 CFR 211.100 to 211.115. Read the regulation on eCFR.

211.100(a)Written production and process control procedures exist, are reviewed and approved by the QCU, and assure product identity, strength, quality, and purity.#3 FDA 483 citation
211.100(b)Procedures are followed and documented at the time of performance, and any deviation is recorded and justified.
211.101Components are weighed or measured accurately, with independent verification of each addition.
211.103Actual yields and percentages of theoretical yield are calculated at the end of each appropriate phase.
211.110(a)In-process controls and tests are defined in writing and performed to monitor output and validate the performance of processes that may cause variability.
211.111Time limits for completing each phase of production are established where appropriate, and deviations are justified.
211.113(b)For sterile products, written procedures prevent microbiological contamination, and aseptic and sterilization processes are validated.#9 FDA 483 citation

21 CFR 211.122 to 211.137. Read the regulation on eCFR.

211.122Labeling and packaging materials are sampled, examined, and released before use, and stored separately with limited access.
211.125Labeling issuance is controlled and reconciled, and discrepancies outside preset limits are investigated.
211.130Packaging and labeling lines are inspected before use (line clearance) to prevent mix-ups, and results are documented.
211.134Packaged and labeled products are examined during finishing operations to confirm correct labels.
211.137Labels carry an expiration date supported by stability testing.

21 CFR 211.142 to 211.150. Read the regulation on eCFR.

211.142Written warehousing procedures keep finished products in quarantine until QCU release and store them under appropriate conditions.
211.150Written distribution procedures ship the oldest approved stock first (with justified exceptions) and allow each lot to be traced for recall.

21 CFR 211.160 to 211.176. Read the regulation on eCFR.

211.160(a)Specifications, standards, sampling plans, and test procedures are written, approved by the QCU, and followed; deviations are recorded and justified.
211.160(b)Laboratory controls are scientifically sound, and instruments are calibrated at suitable intervals under a written program.#4 FDA 483 citation
211.165(a)Each batch is tested against final specifications, including identity and strength of each active ingredient, before release.#10 FDA 483 citation
211.165(e)The accuracy, sensitivity, specificity, and reproducibility of test methods are established and documented.
211.166A written stability program defines sample sizes, test intervals, storage conditions, and stability-indicating methods, and its results support storage conditions and expiration dates.
211.170Reserve samples are kept in the required quantity and storage conditions, and drug product reserve samples are visually examined at least once a year.

21 CFR 211.180 to 211.198. Read the regulation on eCFR.

211.180(a)Production, control, and distribution records are kept at least one year after the batch expiration date and are readily available for inspection.
211.180(e)An annual product review evaluates the quality standards of each drug product at least once a year, including batch records, complaints, recalls, and investigations.
211.186Master production and control records are prepared, dated, and signed by one person and independently checked by a second person.
211.188Batch production and control records document each significant step, with dates, equipment, identity of the people involved, and yield.
211.192The QCU reviews production and control records before release, and every unexplained discrepancy or out-of-specification result is thoroughly investigated, extended to related batches, and documented with conclusions and follow-up.#2 FDA 483 citation
211.194(a)Laboratory records include complete data from every test, including raw data, calculations, and second-person review.
211.198Written complaint procedures exist, the QCU reviews each complaint, and investigations are documented.

21 CFR 211.204 to 211.208. Read the regulation on eCFR.

211.204Returned products are identified, held, and evaluated before any reprocessing or destruction, and records of returns are kept.
211.208Products exposed to improper storage conditions are not salvaged and returned to market unless testing and investigation show they meet all standards.
Audit summary
n/aNot startedScore = full credit for Compliant, half credit for Partial; N/A excluded.
0Compliant
0Partial
0Not compliant
0N/A
0Unanswered
Priority gaps

    Questions paraphrase 21 CFR Part 211 for self-assessment and are not a substitute for the regulation text or an independent audit. Answers are stored only in this browser.

    What a GMP audit checks

    A GMP audit checks whether a site's people, facilities, equipment, materials, processes, laboratories, and records meet current good manufacturing practice. For finished drugs sold in the United States, that standard is 21 CFR Part 211. Auditors do not stop at whether a procedure exists. They test whether it is followed, whether records prove it, and whether the quality unit acts when something goes wrong. That is why the checklist above asks about practice as well as paperwork.

    The 21 CFR 211 sections FDA cites most often

    FDA publishes counts of the regulations cited on Form 483s each year. In fiscal year 2025, the same themes led the drug list again: quality unit procedures, investigations, written procedures, and laboratory controls. The top four sections alone account for nearly a quarter of all Part 211 observations.

    Most cited 21 CFR 211 sections on FDA Form 483s, FY2025Horizontal bar chart. 211.22(d) 243 observations, 211.192 164, 211.100(a) 162, 211.160(b) 121, 211.67(a) 95, 211.68(b) 87, 211.63 81, 211.67(b) 70.050100150200250211.22(d)Quality unit procedures243211.192Investigations164211.100(a)Written procedures162211.160(b)Lab controls121211.67(a)Equipment cleaning95211.68(b)Computer system controls87211.63Equipment design81211.67(b)Cleaning procedures70Number of Form 483 observations (drugs, FY2025)
    Source: FDA Inspection Observations, FY2025 drug data (21 CFR 211 sections), as tabulated by GMP Insiders. Counts are system-generated Form 483 observations and do not include every inspection.

    If you only have time for part of the checklist, start with the items tagged with an FDA 483 rank. Weak investigations under 211.192 are especially costly, because they tend to show up again in warning letters when the same failure repeats.

    How to run a GMP self-audit with this checklist

    1. Scope it. Pick one site, building, or product line, and mark subparts that do not apply as N/A.
    2. Collect evidence, not opinions. For each item, pull a sample record, such as a recent batch record, cleaning log, or OOS investigation, before you answer.
    3. Score honestly. Use Partial whenever a procedure exists but records show it is not followed every time.
    4. Write the note. Record the evidence, the owner, and the next action. Notes print with your summary.
    5. Turn gaps into CAPAs. Prioritize Not compliant items, then Partial items on top-cited sections.

    Self-audit, mock inspection, or FDA inspection?

    Self-auditMock inspectionFDA inspection
    Who runs itInternal QAIndependent auditors acting as investigatorsFDA investigators
    Main goalFind obvious gaps quicklyTest evidence and staff readiness under realistic pressureDetermine compliance; may result in a Form 483
    Typical blind spotWorkarounds the team no longer noticesLimited by time and sample sizeNone you can control

    When to bring in an outside GMP auditor

    Bring in independent auditors when the checklist shows several red subparts, when an FDA or customer inspection is less than six months away, or after a Form 483 or warning letter. DES Pharma's GMP consulting team runs mock inspections and gap assessments, and our FDA remediation group supports responses and CAPA programs. For electronic records, pair this checklist with our ALCOA+ data integrity self-assessment. Medical device and combination product teams can use our ISO 13485 audit checklist.

    Want an independent GMP audit before FDA arrives?

    DES Pharma runs mock inspections, gap assessments, and remediation programs for drug, biologic, and CDMO sites, with findings ranked the way investigators rank them.

    Request a meeting

    GMP audit checklist FAQ

    What is a GMP audit checklist?

    A GMP audit checklist is a structured list of requirements an auditor checks to judge whether a manufacturing site follows current good manufacturing practice. For finished pharmaceuticals in the United States, the requirements come from 21 CFR Part 211, so this checklist is organized by its subparts, from personnel and facilities through laboratory controls and records.

    Does this checklist cover all of 21 CFR Part 211?

    It covers the core requirements in Subparts B through K, focusing on the sections FDA cites most. It does not reproduce every paragraph, and it does not cover related rules such as 21 CFR Part 11 for electronic records, Part 600 for biologics, or EU GMP. Treat it as a first pass, not a complete audit protocol.

    How often should we run an internal GMP audit?

    Part 211 does not set a frequency. Most manufacturers audit every subpart at least once a year and audit higher-risk areas, such as investigations, laboratory controls, cleaning, and data integrity, more often. Audit again after major changes, such as a new product, line, facility, or computer system.

    How is a GMP audit different from a pre-approval inspection?

    A GMP audit checks general compliance with Part 211. A pre-approval inspection is product-specific: FDA checks readiness for commercial manufacturing, whether the site matches what was filed in the NDA or ANDA, and data integrity. A strong GMP audit result is a prerequisite for a PAI, but it is not enough on its own.

    Can a self-audit replace an independent audit?

    No. Self-audits are valuable for finding obvious gaps, but teams tend to score their own systems generously and miss problems they work around every day. An independent auditor tests evidence the way an FDA investigator would, by pulling records, interviewing operators, and following data from instrument to report.

    About DES Pharma Consulting. DES Pharma Consulting (Dynamic Engineering Solutions) supports drug, biologic, and advanced therapy developers with CMC strategy, analytical development, quality control, quality assurance, process development, and supply chain programs, from early development through commercial manufacturing. Contact our team to discuss your program.

    Share

    More Insights:

    Connect With Our Team TodayAdvance Your Drug Program
    with Confidence

    Start building reliable, high-quality drug development programs today.